Your doctor will receive your test results about 10 days after your tumor sample arrives at Rosetta Genomics' labs. This report will show if you have SCLC, carcinoid, squamous NSCLC or non-squamous NSCLC.

The methods currently used to diagnose lung cancer tumor types have limitations and may be inaccurate^1-3. miRview® lung is a unique kind of test. Unlike other tests available, miRview® lung can provide you and your doctor with an accurate diagnosis of SCLC, carcinoid, squamous NSCLC or non-squamous NSCLC.

miRview® lung can tell your doctor if you have SCLC, carcinoid, squamous NSCLC or non-squamous NSCLC. You and your doctor can use this and other information to decide on the best way to move forward in your battle against cancer.

1. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
2. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
3. Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.